Assessment of Fluticasone Propionate on Ocular Allergy Symptoms

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

626 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-12-31

Study Completion Date

2013-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to investigate the efficacy of fluticasone propionate (FP) on ocular symptoms associated with allergic rhinitis (AR).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study Assessing the Dose-response Curve of Fluticasone Propionate in an Antigen Challenge Chamber

NCT00848965

Rhinitis, Allergic, Perennial Allergic Rhinitis

COMPLETED PHASE4

Comparator Study Evaluating Patient Preference Of FFNS vs. FPNS

NCT00539006

Rhinitis, Allergic, Perennial

COMPLETED PHASE4

Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients

NCT02246920

Seasonal Allergic Rhinitis

TERMINATED PHASE3

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic Rhinitis

NCT01231464

Rhinitis, Allergic, Perennial Allergic Rhinitis

COMPLETED PHASE3

A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis

NCT00682643

Rhinitis, Allergic, Perennial

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

While the current FP approved indication for GSK marketed formulation is limited to the treatment of nasal symptoms, several large well-controlled studies in which FP maintained adequate control of nasal symptoms when administered in a dose of 200 micrograms (mcg) once-daily (QD) also suggested improvement in ocular symptoms. This study will employ a randomized, double-blind, parallel group, multi-center design that compares FP and placebo nasal sprays in subjects with seasonal allergic rhinitis (SAR) to assess the effectiveness on ocular symptoms associated with AR.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Allergic Rhinitis Seasonal Allergic Rhinitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fluticasone propionate nasal spray

Fluticasone propionate nasal spray with strength per dose of 50 mcg/spray. Two sprays of study treatment per nostril to be administered in morning.

Group Type EXPERIMENTAL

Fluticasone propionate

Intervention Type DRUG

Nasal spray formulation (200 mcg/day)

Placebo nasal spray

Two sprays of placebo per nostril to be administered in morning.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Vehicle for Fluticasone propionate aqueous nasal spray

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fluticasone propionate

Nasal spray formulation (200 mcg/day)

Intervention Type DRUG

Placebo

Vehicle for Fluticasone propionate aqueous nasal spray

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Flonase

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participants with good general health (in the opinion of the investigator) with no clinically significant and relevant abnormalities of medical history
2. Participants with diagnosis of seasonal allergic rhinitis

1. A clinical history (written or verbal confirmation) of allergic rhinitis with the seasonal onset and offset of nasal and ocular allergy symptoms during each of the last 2 mountain cedar pollen allergy seasons.
2. A positive skin test reaction to (at least) the relevant allergen, mountain cedar pollen, as determined by the skin pricks method performed within 12 months of Visit 1).
3. Participants with allergic rhinitis symptom of at least moderate severity for randomization:

1. An iTOSS of ≥ 4 and an iNCSS of ≥2 on the morning of randomization (Visit 3/Baseline).
2. An averaged (rTOSS) of ≥ 4, and an averaged rNCSS of ≥2 for three of the five days during the placebo lead in
4. Participant residing within a geographical environment where exposure to mountain cedar pollen is significant during the entire study period.
5. Participant demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent/assent and has received a signed and dated copy of the informed consent/assent form. Children, ages 12 to 17 will be required to sign an assent form as part of the informed consent process.

Exclusion Criteria

1. Participants with known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
2. Participants with nasal disorders like:

1. injury or surgery to their nose that the investigator believes would interfere with participation in the study.
2. previously diagnosed with a severe physical obstruction of the nose (e.g., deviated septum) that could affect the deposition of double-blind intranasal study drug.
3. Rhinitis medicamentosa
3. Participants who have historical or current evidence of clinically significant uncontrolled disease like asthma, cardiac arrhythmias, hypertension, diabetes mellitus, ocular herpes, glaucoma, hepatic or renal disease, malignancy etc.
4. Presence of or symptoms of an active bacterial or viral infection.
5. Participants who have conjunctivitis caused by an infectious agent.
6. Participants with current, single eye or bilateral cataracts or participants who had cataract surgery within/less than 3 months

Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes